LONG TERM FOLLOW-UP OF HAIRY CELL LEUKEMIA TREATMENT: 30-YEAR EXPERIENCE AT SINGLE UNIVERSITY CENTER

EHA Library, Jelena Ivanović, 420745

RETREATMENT WITH VENETOCLAX AND RITUXIMAB COMBINATION FOLLOWING DISEASE PROGRESSION WHILE OFF THERAPY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Danielle M. Brander, 420746

SF3B1 MUTATION PREDICTS SHORTENED SURVIVAL IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH IBRUTINIB

EHA Library, Anna Petráčková, 420747

INTERIM RESULTS FROM ASSURE: A PHASE 3B SAFETY STUDY OF ACALABRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Stephen Opat, 420748

REAL-WORLD BRUTON TYROSINE KINASE INHIBITOR TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA IN US COMMUNITY ONCOLOGY PRACTICES

EHA Library, Jing-Zhou Hou, 420749

ANALYSIS OF CLINICAL OUTCOMES OF THE CONSERVATIVE APPROACH IN TREATMENT INDICATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA: INSIGHTS FROM THE BRAZILIAN REGISTRY OF CLL

EHA Library, Celso Arrais-Rodrigues, 420750

ALLOGENIC TRANSPLANTATION IN CHRONIC LYMPHOCYTIC LEUKEMIA IN A SINGLE CENTER: 10 YEARS FOLLOW-UP AND FOCUS ON BTKI/BCL2I DOUBLE EXPOSED CLL

EHA Library, Thérèse Aurran, 420751

PROGNOSTIC RELEVANCE OF THE IMMUNOGLOBULIN LIGHT CHAIN REARRANGEMENT IN TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Mischa Vervoordeldonk, 420752

THE ENDOTHELIAL ACTIVATION AND STRESS INDEX (EASIX) INDEPENDENTLY PREDICTS TIME TO FIRST TREATMENT IN CLL, WHILE ITS IMPACT ON PFS SEEMS TO DEPEND ON THE TREATMENT STRATEGY

EHA Library, Pablo Mozas, 420753

PROGRESSION ON COVALENT BRUTON TYROSINE KINASE INHIBITORS PREDICTS POOR OUTCOMES IN CBTKI-EXPOSED AND CBTKI-VENETOCLAX DOUBLE-EXPOSED POPULATIONS: A RETROSPECTIVE FILO STUDY IN 154 R/R CLL PATIENTS

EHA Library, Loïc Ysebaert, 420754

IMPACT OF FIRST-YEAR DOSE MODIFICATIONS OF ACALABRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Alessandra Tedeschi, 420755

SCOPING OUT CARDIOVASCULAR ASSESSMENT ON INITIATION AND SUBSEQUENT MONITORING DURING BTKI THERAPY, AN ERIC INITIATIVE

EHA Library, Thomas Chatzikonstantinou, 420756

INCIDENTAL LYMPHADENOPATHY AND SPLENOMEGALY ON IMAGING STUDIES CAN PREDICT TIME TO FIRST CLL THERAPY AND OVERALL SURVIVAL IN PATIENTS WITH CLL-LIKE HIGH COUNT MONOCLONAL B-CELL LYMPHOCYTOSIS

EHA Library, Samuel Kosydar, 420757

COMPARATIVE EFFECTIVENESS OF IBRUTINIB FLEXIBLE DOSING TREATMENT STRATEGIES ON TIME TO NEXT TREATMENT IN A LARGELY COMMUNITY-BASED CLAIMS DATABASE: A TARGET TRIAL EMULATION STUDY

EHA Library, Nilanjan Ghosh, 420758

POT1 MUTATIONS IDENTIFY INFERIOR OUTCOMES IN CHRONIC LYMPHOCYTIC LEUKEMIA AND DISRUPTED TELOMERE BIOLOGY FUNCTION

EHA Library, Bihui Pan, 420759

COMPARISON OF TIME TO NEXT TREATMENT BETWEEN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA INITIATING FIRST-LINE IBRUTINIB OR ACALABRUTINIB OVERALL AND IN A SUBGROUP WITH HIGH-RISK CHARACTERISTICS

EHA Library, Ryan Jacobs, 420760

REAL-WORLD TREATMENT SWITCHING AND SEQUENCING TO NEXT LINE OF THERAPY OF ZANUBRUTINIB, ACALABRUTINIB, AND IBRUTINIB IN CLL/SLL

EHA Library, Javier Pinilla-Ibarz, 420761

ZANUBRUTINIB VS OTHER BRUTON’S TYROSINE KINASE INHIBITORS IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: A MULTILEVEL NETWORK META-REGRESSION

EHA Library, Mazyar Shadman, 420762

6-YEAR TIME TO NEXT TREATMENT (TTNT) EXTRAPOLATION CURVE FOR GLOW STUDY: FIRST-LINE IBRUTINIB + VENETOCLAX (I+V) OFFERS LONG TREATMENT-FREE PERIOD FOR ELDERLY/UNFIT CLL PATIENTS

EHA Library, Santiago Ossorio Prendes, 420763

EFFICACY OF ZANUBRUTINIB VERSUS ACALABRUTINIB IN THE TREATMENT OF RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL): A MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC)

EHA Library, Mazyar Shadman, 420764

COMPARATIVE EFFICACY OF BRUTON TYROSINE KINASE INHIBITORS IN THE TREATMENT OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: A NETWORK META-ANALYSIS

EHA Library, Mazyar Shadman, 420765

EFFICACY AND SAFETY OF ZANUBRUTINIB VS. VENETOCLAX+IBRUTINIB IN THE TREATMENT-NAÏVE (TN) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC)

EHA Library, Talha Munir, 420766

IMPACT OF ACALABRUTINIB TREATMENT BY LINE OF THERAPY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: POOLED ANALYSIS FROM ELEVATE-TN, ELEVATE-RR, AND ASCEND

EHA Library, Paolo Ghia, 420767

IBROMICS: A REAL-WORLD STUDY OF CLINICAL AND BIOLOGICAL PARAMETERS DETERMINING RESPONSE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATED IN FIRST LINE WITH SINGLE AGENT IBRUTINIB.

EHA Library, JOSE ANGEL HERNANDEZ RIVAS, 420768

C3G DEFICIENCY DELAYS CHRONIC MYELOID LEUKEMIA DEVELOPMENT IN A P210 BCR-ABL1 TRANSGENIC MODEL

EHA Library, Pablo Berrocal Navarro, 420769

DESIGN AND VALIDATION OF A MASS CYTOMETRY APOPTOTIC PANEL FOR PREDICTING SENSITIVITY OF CHRONIC MYELOID BLAST CELLS CROSS-RESISTANT TO TYROSINE KINASE INHIBITORS TO THE BCL2 INHIBITOR VENETOCLAX

EHA Library, Adam Laznicka, 420770

MAKING TKI DISCONTINUATION MORE EFFICIENT IN CHRONIC MYELOID LEUKEMIA: THE ROLE OF CIRCULATING CYTOKINES AND RESIDUAL PRIMITIVE LEUKEMIC CELLS.

EHA Library, Michele Bianchini, 420771

MODELING SRSF2/TET2 MUTATIONAL COOPERATIVITY IN CMML DEVELOPMENT

EHA Library, Dina Alihodzic, 420773

KF-1601, A DUAL INHIBITOR BCR::ABL1 AND FLT3, OVERCOMES DRUG RESISTANCE IN FLT3+ BLAST PHASE CHRONIC MYELOGENOUS LEUKEMIA

EHA Library, Sung-Min Ahn, 420774

UPDATE OF THE FRENCH STOP IMATINIB STUDY (STIM1) EXTENDED LONG TERM FOLLOW UP.

EHA Library, François-Xavier Mahon, 420776

EUROPEAN LEUKEMIANET MILESTONES AND THEIR PROGNOSTIC RELEVANCE FOR ACHIEVING DEEP MOLECULAR RESPONSE AND TREATMENT-FREE REMISSION IN ROUTINE CARE: RESULTS OF THE GERMAN CML REGISTRY

EHA Library, Katharina Kohlbrenner, 420777

TYROSINE KINASE INHIBITORS DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA: A RETROSPECTIVE ANALYSIS OF 657 ITALIAN PATIENTS

EHA Library, Valentina Bonuomo, 420778

DEEP MOLECULAR RESPONSE RATE IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA. ELIGIBILITY TO DISCONTINUATION RELATED TO TIME TO RESPONSE AND DIFFERENT FRONTLINE TKI: THE LABNET CML NATIONAL NETWORK

EHA Library, Massimo Breccia, 420779

IMPROVEMENT OF TREATMENT-FREE REMISSION RATE FOLLOWING DISCONTINUATION OF BCR::ABL1 TKI WITH A FASTER INITIAL DECLINE OF BCR::ABL1 TRANSCRIPT AND LONGER TREATMENT DURATION IN CHRONIC MYELOID LEUKEMIA

EHA Library, SEWON LEE, 420780

ONE YEAR ANALYSIS OF GROWTH DATA IN NEWLY-DIAGNOSED PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH BOSUTINIB: RESULTS FROM TRIAL ITCC-054/COG-AAML1921

EHA Library, Edoardo Pennesi, 420781

RESULTS OF PONATINIB AS FRONTLINE THERAPY FOR CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE

EHA Library, Fadi Haddad, 420782

LOWER-DOSE INITIATING BOSUTINIB IS SAFE AND EFFECTIVE FOR RESISTANT OR INTOLERANT TO PRIOR THERAPY CHRONIC MYELOID LEUKEMIA PATIENTS (BOGI TRIAL): A SINGLE-ARM, MULTICENTER, PHASE II TRIAL

EHA Library, Shinya Kimura, 420783

ASC4REAL: EFFICACY AND TOLERABILITY COMPARISON BETWEEN ASCEMBL STUDY, A PHASE 3 RANDOMIZED CLINICAL TRIAL (RCT), AND REAL-WORLD (RW) EXPERIENCE WITH ASCIMINIB IN CML PATIENTS BEYOND 2 TKIS

EHA Library, Anchit Khanna, 420784

CLINICAL EFFICACY OF FIRST-LINE NILOTINIB OR IMATINIB THERAPY IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA – NATIONWIDE REAL LIFE DATA

EHA Library, Daniela Zackova, 420785

OLVEREMBATINIB OVERCOMES PONATINIB AND ASCIMINIB RESISTANCE IN PATIENTS (PTS) WITH HEAVILY PRETREATED CHRONIC MYELOID LEUKEMIA (CML) AND PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH⁺ ALL)

EHA Library, Elias Jabbour, 420786

BCR::ABL1 KINETICS IN CHRONIC PHASE (CP) CHRONIC MYELOID LEUKEMIA (CML) PATIENTS AFTER PONATINIB VERSUS NILOTINIB TREATMENT FRONT-LINE

EHA Library, Franck Emmanuel Nicolini, 420787

TREATMENT PATTERNS AND REAL-WORLD CLINICAL OUTCOMES OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE TREATED WITH ASCIMINIB IN ONCOLOGY PRACTICES IN THE UNITED STATES

EHA Library, Ehab Atallah, 420788

PROPENSITY SCORE MATCHING ANALYSIS COMPARING ASCIMINIB VERSUS PONATINIB FOR ITS TREATMENT OUTOMES IN CHRONIC MYELOID LEUKEMIA PATIENTS

EHA Library, Maria Agustina Perusini, 420789

IL10 AND IL15 SIGNIFICANTLY PLUMMETED IN PATIENTS PRESENTING WITH TYROSINE KINASE INHIBITOR WITHDRAWAL SYNDROME (TWS). PRELIMINARY RESULTS FROM THE « KIWIS » STUDY DESIGNED FOR TWS.

EHA Library, Hyacinthe Atchroue Johnson Ansah, 420790

ANALYSIS OF FACTORS AFFECTING THE ACQUISITION OF MR4.5 UNDER FIRST-LINE IMATINIB TREATMENT

EHA Library, Jian Huang, 420792

KRAS MUTATION PREDICTS POOR OUTCOME IN PATIENTS WITH MYELOID BLAST PHASE CHRONIC MYELOID LEUKEMIA RECEIVING THIRD GENERATION TYROSINE KINASE INHIBITORS COMBINED WITH AZACITIDINE

EHA Library, Mei Bao, 420793

ASCIMINIB AS INITIAL THERAPY FOR PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (ALERTCML)

EHA Library, Ehab Atallah, 420794

DECIPHERING TELOMERES VARIANTS IN MYELOID NEOPLASMS: INSIGHTS INTO TERT VARIANTS OF UNCERTAIN SIGNIFICANCE.

EHA Library, Ludovica Marando, 420795

CHARACTERIZATION OF THE MOLECULAR SIGNATURE OF HUMAN MONOCYTES IN MYELODYSPLASTIC SYNDROME AND AGING.

EHA Library, Ioannis Kotsianidis, 420796

GENETIC CHARACTERIZATION OF CHIP IN CARDIOVASCULAR DISEASES IN COMPARISON TO MYELOID MALIGNANCIES

EHA Library, Manja Meggendorfer, 420797

GENOTYPE/PHENOTYPE ASSOCIATIONS IN MDS - HOW GENETICS IMPACT CYTOPENIA

EHA Library, Sandra Huber, 420798

MOLECULAR LANDSCAPE OF A MDS/MPN COHORT

EHA Library, Diana Margarita Trejos Carvajal, 420799

PATHOGENESIS OF MYELOID NEOPLASMS WITH DER(1;7)(Q10;P10)

EHA Library, Rurika Okuda, 420800

MORPHOLOGY-INSPIRED GENETIC GROUPS FOR STRATIFICATION OF MDS PATIENTS WITH INCREASED BLASTS

EHA Library, Maki Sakuma, 420801

CLASSIFICATION AND PROGNOSTIC STRATIFICATION BASED ON GENOMIC FEATURES IN MYELOID DYSPLASTIC NEOPLASMS, MYELOPROLIFERATIVE NEOPLASMS AND THEIR OVERLAPPING CONDITIONS.

EHA Library, Jong-Mi Lee, 420802

U2AF1 S34F MUTATION CAUSED DYS-MEGAKARYOPOIESIS THROUGH CHK1 ABERRANT SPLICING IN MDS

EHA Library, Wenjun Zhang, 420803

MDS-PB13 SCORE - A NEW SCREENING METHOD FOR MDS ASSOCIATED ABERRANCIES BY FLOW CYTOMETRY IN BLOOD: IMPLICATIONS FOR DIAGNOSIS AND PROGNOSIS

EHA Library, Uta Oelschlaegel, 420804

SENECTUS IPSA MORBUS EST? HOW TO DISTINGUISH INFLAMMAGING FROM INFLAMMATION OF MYELODYSPLASTIC SYNDROMES BY AN ARTIFICIAL INTELLIGENCE APPROACH.

EHA Library, elena tofacchi, 420805

SOMATIC MUTATIONS AND DNA METHYLATION IDENTIFY A SUBGROUP OF POOR PROGNOSIS WITHIN LOWER RISK MYELODYSPLASTIC SYNDROMES

EHA Library, Michaela Fontenay, 420806

PARALLEL MONITORING OF MEASURABLE RESIDUAL DISEASE AND CHIMERISM BY NGS IN MYELODYSPLASTIC SYNDROME AFTER ALLOGENIC STEM CELL TRANSPLANT

EHA Library, Irene Zamanillo, 420807

TARGETING DYSREGULATION OF IRON HOMEOSTASIS IN MDS MICE WITH AN OPTIMISED GALNAC-CONJUGATED TMPRSS6 SIRNA

EHA Library, Jim Vadolas, 420808

CD56 EXPRESSION IN MYELODYSPLASTIC SYNDROMES: REVIEWING OLD DATA WITH FRESH EYES.

EHA Library, Valerie BARDET, 420809

CLONAL HIERARCHY OF SOMATIC MUTATIONS IN MYELODYSPLASTIC NEOPLASMS

EHA Library, Claudia Haferlach, 420810

NAMPT INHIBITORS TARGET MYELOBLASTS FROM HIGH-RISK MDS PATIENTS WITH MONOSOMY 7 OR DELETION 7Q

EHA Library, Nemo Ikonen, 420811

NHEJ DNA-REPAIR PATHWAY GERMLINE VARIANTS IN EARLY-ONSET ADULT MYELODYSPLASTIC SYNDROMES: HOMOLOGOUS RECOMBINATION DEFICIENCY SCORE AND CLINICAL IMPACT

EHA Library, Maria Gabarrós-Subirà, 420812

COMPARATIVE ANALYSIS OF CLINICAL BENEFIT BY GENOMIC LANDSCAPE AND MUTATIONAL BURDEN OF LUSPATERCEPT VERSUS EPOETIN ALFA IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS) IN THE PHASE 3 COMMANDS STUDY

EHA Library, Rami S. Komrokji, 420813

ELTROMBOPAG RESTORES PROLIFERATIVE CAPACITY AND ADIPOSE-OSTEOGENIC BALANCE OF MESENCHYMAL STROMAL CELLS IN PATIENTS WITH LOW-RISK MYELODYSPLASTIC SYNDROMES

EHA Library, Minghua Hong, 420814

POLY(RC)-BINDING PROTEIN 1 REPRESSES FERROPTOSIS IN ANEMIA OF MYELODYSPLASTIC SYNDROMES  THROUGH THE P53/SLC7A11/ALOX12 PATHWAY

EHA Library, Mengying Zhang, 420815

CLONAL HIERARCHY OF PPM1D MUTATION IMPACTS RISK OF TRANSFORMATION TOWARDS THERAPY-RELATED MYELOID NEOPLASMS

EHA Library, David Fandrei, 420816

SINGLE CELL PROFILING OF DEL(5Q) MDS UNVEILS ITS TRANSCRIPTIONAL LANDSCAPE AND THE IMPACT OF LENALIDOMIDE

EHA Library, Nerea Berastegui Zufiaurre, 420817

DNA METHYLATION PROFILING OF MYELODYSPLASTIC SYNDROMES AND CLINICAL RESPONSE TO AZACITIDINE: A MULTICENTER RETROSPECTIVE STUDY

EHA Library, Ignacio Campillo-Marcos, 420818

IDENTIFICATION OF TRANSCRIPTIONAL ALTERATIONS LEADING TO ABERRANT MYELOID DIFFERENTIATION IN MYELODYSPLASTIC SYNDROMES

EHA Library, Aintzane Díaz-Mazkiaran, 420819

HIGH PROPORTION OF CD95+/CD45RA- REGULATORY T CELLS IN THE BONE MARROW OF MDS PATIENTS IS A BIOMARKER OF IMMUNE SUPPRESSION AND A HIGHER RISK OF PROGRESSION.

EHA Library, Nicolas Chapuis, 420820

MYELODYSPLASTIC SYNDROMES BENEFIT OF IRON-RESTRICTED BONE MARROW TRANSPLANTATION IN PRECLINICAL STUDIES

EHA Library, Francesca Vinchi, 420821

PRIMARY U2AF1(S34F) MUTATED HEMATOPOIETIC CELLS ARE SENSITIVE TO NONSENSE-MEDIATED RNA DECAY DISRUPTION IN VIVO

EHA Library, Claudia Cabrera, 420822

DEVELOPMENT OF PATIENT DERIVED XENOGRAFT (PDX) MODELS OF MYELODYSPLASTIC SYNDROMES

EHA Library, Ângela Mesquita, 420823

ACTIVIN A INHIBITION BY ELRITERCEPT (KER-050) IS ASSOCIATED WITH EVIDENCE OF CARDIOVASCULAR BENEFIT: TRANSLATION OF PRECLINICAL OBSERVATIONS TO HUMANS WITH MDS

EHA Library, Shuhying Tan, 420824

TELOMERE BIOLOGY DRIVES AND SHAPES THE LANDSCAPE OF CLONAL MYELOID DISORDERS IN OLD AGE

EHA Library, Matthew McLoughlin, 420825

PATHOGENIC ROLES OF DDX41 MUTATIONS IN THE DEVELOPMENT OF MYELOID MALIGNANCIES

EHA Library, Ayana Kon, 420826

LUSPATERCEPT IMPROVES HEMATOPOIESIS IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS): COMPARATIVE BIOMARKER ANALYSIS OF RING SIDEROBLAST-POSITIVE AND -NEGATIVE SUBGROUPS FROM THE PHASE 3 COMMANDS STUDY

EHA Library, Uwe Platzbecker, 420827

UNRAVELING PATHOPHYSIOLOGY AND HEMATOPOIESIS OF VEXAS SYNDROME BY MULTI-OMICS ANALYSES AND TARGETED GENE EDITING

EHA Library, Samuele Ferrari, 420828

MOLECULAR AND CLINICAL CHARACTERIZATION OF ETNK1-MUTATED MYELOID NEOPLASMS: THE MAYO CLINIC EXPERIENCE AND FUTURE DIRECTIONS

EHA Library, Steven Tessier, 420829

EXPLORING SEX-DIVERSITY OF GENE MUTATIONS AND RESPONSE TO ESA TREATMENT IN LOW-RISK MYELODYSPLASTIC NEOPLASMS

EHA Library, Marco Raddi, 420830

IMPACT OF COMPLETE CYTOGENETIC RESPONSE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES

EHA Library, Samuel Urrutia, 420831

REAL-WORLD DOSE ESCALATION AND OUTCOMES AMONG PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES RECEIVING LUSPATERCEPT IN CLINICAL PRACTICE

EHA Library, Kashyap Patel, 420832

THE HUMANISTIC AND ECONOMIC BURDEN OF TRANSFUSION-DEPENDENT LOWER-RISK MYELODYSPLASTIC SYNDROMES ON PATIENTS IN NORTH AMERICA AND EUROPE

EHA Library, María Díez Campelo, 420833

ORAL DECITABINE/CEDAZURIDINE WITH VENETOCLAX VERSUS ORAL DECITABINE/CEDAZURIDINE IN HIGH-RISK MYELODYSPLASTIC SYNDROME: A PROPENSITY SCORE MATCHED ANALYSIS

EHA Library, Alex Bataller, 420834

ASSESSMENT OF CLINICAL OUTCOMES OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) WHO WERE TREATED WITH ORAL DECITABINE/CEDAZURIDINE (DEC-C) USING THE INTERNATIONAL WORKING GROUP (IWG) 2023 CRITERIA

EHA Library, Amer M. Zeidan, 420835

CLINICAL IMPLICATIONS OF SPLICING FACTOR MUTATIONS IN PATIENTS WITH HIGHER RISK MYELODYSPLASTIC SYNDROMES/NEOPLASMS TREATED WITH HYPOMETHYLATING AGENTS (HMA)- A MULTICENTER, RETROSPECTIVE ANALYSIS

EHA Library, Tariq Kewan, 420836

PHASE 1B STUDY OF SL-172154, A BI-FUNCTIONAL FUSION PROTEIN TARGETING CD47 AND CD40, WITH AZACITIDINE IN PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA AND HIGHER-RISK MYELODYSPLASTIC SYNDROMES

EHA Library, Amer Zeidan, 420837

RELATIONSHIP BETWEEN HAEMOGLOBIN AND QUALITY OF LIFE IN TRANSFUSION-DEPENDENT PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROME RECEIVING LUSPATERCEPT OR EPOETIN ALFA

EHA Library, Esther N. Oliva, 420838

CLINICAL IMPLICATIONS OF IDH MUTATIONS (IDH MT) IN PATIENTS (PTS) WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES/NEOPLASMS (MDS) TREATED WITH HYPOMETHYLATING AGENTS (HMA)

EHA Library, Tariq Kewan, 420839

CPH DEEP NEURAL NETWORK DEMONSTRATES THAT IWG-2023-PROPOSED LOWERING OF HB THRESHOLD TO ≥10G/DL FOR RESPONSE ASSESSMENT DOES NOT RESULT IN WORSE OUTCOME PREDICTION THAN ≥11G/DL AS ASSESSED BY PB-CR

EHA Library, Lisa Pleyer, 420840

PREVALENCE AND CLINICAL SIGNIFICANCE OF GERMLINE VARIANTS IN CEBPA, DDX41, ETV6, GATA2 AND RUNX1 AMONG PATIENTS WITH MYELODYSPLASTIC SYNDROMES

EHA Library, Anna Tranberg, 420841

REAL-LIFE ANEMIA TREATMENT   IN LOW-RISK MYELODYSPLATIC SYNDROME (MDS) PATIENTS: A RETROSPECTIVE MULTICENTER STUDY BY THE GROUPE FRANCOPHONE DES MYÉLODYSPLASIES (GFM) ON 194 PATIENTS

EHA Library, abdessamia gandoul, 420842

MULTILINEAGE AND SAFETY RESULTS FROM THE COMMANDS TRIAL IN TRANSFUSION-DEPENDENT, ERYTHROPOIESIS-STIMULATING AGENT-NAIVE PATIENTS WITH VERY LOW-, LOW-, OR INTERMEDIATE-RISK MYELODYSPLASTIC SYNDROMES

EHA Library, Guillermo Garcia-Manero, 420844

PERIPHERAL BLOOD COMPLETE REMISSION (PB-CR) IS ASSOCIATED WITH SIMILAR SURVIVAL AS CR PER IWG 2023 CRITERIA IN PATIENTS WITH HIGHER-RISK MDS – AN INTERNATIONAL STUDY FROM THE VALIDATE CONSORTIUM

EHA Library, Tariq Kewan, 420845

QUANTIFYING THE RELATIONSHIP BETWEEN TRANSFUSION INDEPENDENCE AND OVERALL SURVIVAL IN LOWER-RISK MYELODYSPLASTIC SYNDROMES

EHA Library, Luca Malcovati, 420846

SPECTRUM AND CLINICAL IMPLICATIONS OF EXTRAMEDULLARY MANIFESTATIONS IN CHRONIC MYELOMONOCYTIC LEUKEMIA

EHA Library, Guillermo Montalban-Bravo, 420847

CHARACTERISATION AND PROGNOSTIC IMPACT OF ZRSR2 MUTATIONS IN MYELOID NEOPLASMS

EHA Library, Aref Al-Kali, 420848